Home > Insider Trading > Filing (0001209191-15-053996)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1463729	Receptos Inc.	RCPT	Pharmaceutical Preparations (2834)	264190792

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1552293	Edward S. Torres	C/O Receptos, Inc. 3033 Science Park Road, Suite 300 San Diego CA 92121		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-06-12	81,200	$180.33	804,361	No	4	S	Indirect	See footnote
Common Stock	Disposition	2015-06-15	88,400	$175.54	715,961	No	4	S	Indirect	See footnote
Common Stock	Disposition	2015-06-16	50,400	$182.89	665,561	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	7,400	Direct

Footnotes

The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $178.05 to $182.18 per share, inclusive. The reporting person undertakes to provide to Receptos, Inc., any security holder of Receptos, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (1), (3) and (4).
These shares are owned directly by Lilly Ventures Fund I, LLC (the "Fund"). Eli Lilly and Company, as sole Managing Member of the Fund, and pursuant to provisions of the LLC Agreement of the Fund, has voting authority with respect to shares owned by the Fund. S. Edward Torres is a non-managing member of the Fund and may be deemed to beneficially own the shares. Mr. Torres disclaims beneficial ownership of the shares held of record by the Fund, except to the extent of his pecuniary interest therein.
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $175.00 to $177.49 per share, inclusive.
The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $175.00 to $188.28 per share, inclusive.
Represents time-based restricted stock units which vest 100% on the first anniversary of the 5-28-15 date of grant.